ES2568881T3 - Inhibición de la angiogénesis - Google Patents

Inhibición de la angiogénesis Download PDF

Info

Publication number
ES2568881T3
ES2568881T3 ES08832515.4T ES08832515T ES2568881T3 ES 2568881 T3 ES2568881 T3 ES 2568881T3 ES 08832515 T ES08832515 T ES 08832515T ES 2568881 T3 ES2568881 T3 ES 2568881T3
Authority
ES
Spain
Prior art keywords
vegf
antibody
human
antibodies
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08832515.4T
Other languages
English (en)
Spanish (es)
Inventor
Napoleon Ferrara
Farbod Shojaei
Xiumin Wu
Cuiling Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2568881T3 publication Critical patent/ES2568881T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
ES08832515.4T 2007-09-21 2008-09-19 Inhibición de la angiogénesis Active ES2568881T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97438207P 2007-09-21 2007-09-21
US974382P 2007-09-21
US8307108P 2008-07-23 2008-07-23
US83071P 2008-07-23
PCT/US2008/076954 WO2009039337A2 (en) 2007-09-21 2008-09-19 Inhibition of angiogenesis

Publications (1)

Publication Number Publication Date
ES2568881T3 true ES2568881T3 (es) 2016-05-05

Family

ID=40030248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08832515.4T Active ES2568881T3 (es) 2007-09-21 2008-09-19 Inhibición de la angiogénesis

Country Status (19)

Country Link
US (1) US9284369B2 (https=)
EP (1) EP2203479B1 (https=)
JP (1) JP5615709B2 (https=)
KR (1) KR101578945B1 (https=)
CN (1) CN102037015B (https=)
AR (1) AR068532A1 (https=)
AU (1) AU2008302214B2 (https=)
CA (1) CA2700276A1 (https=)
CL (1) CL2008002782A1 (https=)
CO (1) CO6270370A2 (https=)
ES (1) ES2568881T3 (https=)
IL (1) IL204502A (https=)
MX (1) MX2010003013A (https=)
NZ (1) NZ584787A (https=)
PE (1) PE20091197A1 (https=)
RU (2) RU2471498C2 (https=)
TW (1) TWI457349B (https=)
WO (1) WO2009039337A2 (https=)
ZA (1) ZA201001868B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL368972A1 (en) * 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CA2679867A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
RU2567803C2 (ru) * 2009-07-31 2015-11-10 Дженентек, Инк. ИНГИБИРОВАНИЕ МЕТАСТАЗИРОВАНИЯ ОПУХОЛИ ПРИ ПОМОЩИ АНТАГОНИСТОВ Bv8 ИЛИ G-CSF
DK2488554T3 (da) 2009-10-14 2019-09-02 Humanigen Inc Antistoffer mod epha3
RU2559542C2 (ru) 2009-12-23 2015-08-10 Дженентек, Инк. Антитела против bv8 и их применение
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド Ｇ−ｃｓｆｒに対する抗体およびその使用
CA2842481A1 (en) * 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013148285A1 (en) * 2012-03-30 2013-10-03 The General Hospital Corporation Methods of inhibiting cell proliferation
TWI498425B (zh) * 2013-01-08 2015-09-01 Nat Univ Tsing Hua 層析濾紙型酵素連結免疫吸附分析法
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
KR102359396B1 (ko) * 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
CN104237223B (zh) * 2014-10-08 2017-04-12 江苏奥赛康药业股份有限公司 测定铁‑碳水化合物络合物中不稳定铁含量的方法
CN104587469A (zh) * 2015-01-19 2015-05-06 马洁 G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用
TWI746491B (zh) * 2015-12-03 2021-11-21 財團法人國家衛生研究院 異質雙聚體型血管內皮生長因子及其應用
WO2018108862A1 (en) * 2016-12-12 2018-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20260036321A (ko) 2023-07-05 2026-03-16 씨에스엘 이노베이션 피티와이 엘티디 겸상적혈구병의 합병증을 치료하거나 예방하는 방법
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
PL368972A1 (en) * 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
JP4912144B2 (ja) * 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CN1802169A (zh) * 2003-03-12 2006-07-12 健泰科生物技术公司 Bv8和/或EG－VEGF促进造血的用途
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
CA2622575A1 (en) * 2005-09-13 2007-03-22 Zymogenetics, Inc. Prok2 antagonists and methods of use
ITRM20070182A1 (it) * 2007-04-03 2008-10-04 Univ Roma Antagonisti dei recettori delle prochineticine derivati di essi e loro uso

Also Published As

Publication number Publication date
EP2203479A2 (en) 2010-07-07
US20100316633A1 (en) 2010-12-16
JP2010540449A (ja) 2010-12-24
WO2009039337A3 (en) 2009-05-14
IL204502A (en) 2015-05-31
CN102037015B (zh) 2016-02-03
AR068532A1 (es) 2009-11-18
CL2008002782A1 (es) 2009-07-31
ZA201001868B (en) 2011-06-29
RU2012140185A (ru) 2014-03-27
NZ584787A (en) 2012-12-21
HK1141538A1 (zh) 2010-11-12
CO6270370A2 (es) 2011-04-20
CA2700276A1 (en) 2009-03-26
WO2009039337A2 (en) 2009-03-26
KR20100075513A (ko) 2010-07-02
KR101578945B1 (ko) 2015-12-21
US9284369B2 (en) 2016-03-15
RU2471498C2 (ru) 2013-01-10
AU2008302214A1 (en) 2009-03-26
TWI457349B (zh) 2014-10-21
MX2010003013A (es) 2010-08-02
PE20091197A1 (es) 2009-08-14
RU2010115755A (ru) 2011-10-27
TW200920750A (en) 2009-05-16
EP2203479B1 (en) 2016-01-27
AU2008302214B2 (en) 2012-10-25
CN102037015A (zh) 2011-04-27
JP5615709B2 (ja) 2014-10-29

Similar Documents

Publication Publication Date Title
ES2568881T3 (es) Inhibición de la angiogénesis
US10487147B2 (en) Anti-PD-L1 antibodies and uses thereof
ES2742379T3 (es) Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
TWI577695B (zh) 用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
AU2018377852B2 (en) Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
CN102498129B (zh) 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
EP3355902B1 (en) Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
ES2808529T3 (es) Inhibidor del factor de células madre
IL259486B2 (en) Substances for the treatment of diseases associated with unwanted cell proliferation
CN103890008A (zh) 在顽固性肿瘤中抑制血管发生
US20250163150A1 (en) Combination therapies comprising a kras inhibitor for the treatment of cancer
JPWO2015025770A1 (ja) 疼痛抑制物質のスクリーニング方法および疼痛の予防または治療用医薬組成物
WO2011006001A1 (en) Animal model for the evaluation of adjuvant therapies of cancer
US20200282010A1 (en) Immunogenic compositions and uses therefor
HK1194394A (en) Inhibition of angiogenesis in refractory tumors